SynaptiCure has raised $25 million for its virtual approach to neurodegenerative disease care.

SALT LAKE CITY, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN), through its wholly owned subsidiary Clene Nanomedicine Inc. in collaboration with Columbia University and Synapticure, has been awarded a four-year grant totaling $45.1 million from the National Institute of Neurological Disorders and Stroke (NINDS), a division of the National Institutes of Health (NIH), to support an Expanded Access Protocol (EAP) for the Company’s investigational drug, CNM-Au8®, in amyotrophic lateral sclerosis (ALS). An EAP is also referred to as Compassionate Use and is an FDA-regulated pathway that allows people with a serious and life-threatening disease to access an investigational drug that is not yet approved by the U.S. Food and Drug Administration (FDA)

As the first nationwide virtual clinic specializing in neurodegenerative disease, Synapticure scales leadership team to meet the rapidly growing needs of patients, payers and providersCHICAGO, Sept. 6, 2023 /PRNewswire/ -- Synapticure , a virtual clinic transforming treatment and outcomes for individuals and their caregivers living with neurodegenerative diseases, announced Joe Leinbach has joined as the company's first Chief Operating Officer. Leinbach joins at a critical time for the company's expansion into additional neurodegenerative conditions including Alzheimer's and related Dementias, while creating new ways to expand patient access through innovative partnerships with health systems and health plans.A veteran of early stage value-based care innovators, Leinbach has driven growth and operational success in leadership roles at Cityblock Health and Evolent Health. His background includes scaling operations to serve individuals with complex physical and behavioral health needs, and structuring partnerships with payers and providers to improve patient costs and outcomes. Joe will lead the company's next phase of growth and efforts to implement innovative models that directly benefit patients and partners.Founded in 2021 by Brian Wallach and Sandra Abrevaya, the co-founders of I AM ALS , Synapticure's care teams now provide services to all 50 states + DC, providing specialized neurology care, integrated behavioral health, and care coordination to help patients and their caregivers navigate the complexities of neurodegenerative diseases. Through proactive, patient-centered support, Synapticure's patients have enrolled in clinical trials they otherwise wouldn't have accessed, were prescribed new medications and supplements changing their quality of life, avoided costly hospitalizations and ER visits, and received support for issues with medical equipment, insurance benefits and other care needs.Story continues"We've proven that patients and caregivers love working with Synapticure's specialized neurologists, as shown by our incredible NPS (Net Promoter Score) of 95